Events

LabCentral's newest Innovation Partner, Breakthrough T1D, is launching their first Golden Tickets! 

Apply here by August 29th to be considered.

Breakthrough T1D invites startups and early-stage companies pursuing research relevant to our Disease Modifying Therapies (DMT) and Cell Therapies (CT) research strategies to apply. Breakthrough T1D’s overall goal is to deliver therapies that prevent the onset of Type 1 Diabetes (T1D) and restore pre-diabetes physiology in people with established T1D.  Areas of particular interest include:

DMT

• Immune Modulation – Therapies to disable autoreactivity, enhance immune regulation, or redirect the inflammatory process
• Beta Cell Protection – Approaches to improve beta cell survival and function in the face of autoimmune attack
• Beta Cell Regeneration – Strategies to stimulate growth, proliferation, or differentiation of functional beta cells in vivo

CT

• Immune Protection – Localized immune modulation, novel immune suppression, or alternative strategies to protect transplanted pancreatic islets
• Alternative Implantation Sites – Novel approaches for delivery of pancreatic islets beyond portal vein infusion
• Vascularization and Engraftment – Technologies to enhance survival and integration of islets post-transplantation
• Monitoring and Biomarkers – Systems for non-invasive monitoring of implanted islets and biomarkers for beta cell health or transplant rejection

Applicants are encouraged to review Breakthrough T1D’s research strategy document to better understand our DMT and CT priorities. Please note that we are not considering technologies within our Early Detection or Improving Lives programs for this opportunity. Strategic fit and scientific inquiries may be directed to Alan Chiu (achiu@breakthrought1d.org). 

Applications will be judged using the following criteria:

• Alignment with Breakthrough T1D’s DMT and CT research strategies
• Scientific rationale and supporting data for application in T1D
• Innovation and differentiation from existing approaches
• Potential for clinical impact and improved outcomes for T1D patients